Catalog No.
DHD80801
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Cyclic ADP-ribose hydrolase 1, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase, T10, 2'-phospho-cyclic-ADP-ribose transferase, CD38, ADPRC 1, ADP-ribosyl cyclase 1, 2'-phospho-ADP-ribosyl cyclase
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P28907
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
HuMax-CD38, CAS: 945721-28-8
Clone ID
Daratumumab
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma, PMID: 27557302
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma, PMID: 31141632
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma, PMID: 27705267
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA, PMID: 32244252
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study, PMID: 32682484
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma, PMID: 29231133
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma, PMID: 31113777
Daratumumab for the treatment of AL amyloidosis, PMID: 30033840
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial, PMID: 32213342
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma, PMID: 28637662
Daratumumab in multiple myeloma, PMID: 30951198
Daratumumab for the treatment of multiple myeloma, PMID: 28434255
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus, PMID: 32937047
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR, PMID: 30237264
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma, PMID: 31936617
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial, PMID: 31836199
Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis, PMID: 33387628
Daratumumab subcutaneous formulation for the treatment of multiple myeloma, PMID: 32750265
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma, PMID: 31270103
[Daratumumab for multiple myeloma], PMID: 30430991
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma, PMID: 27222480
Daratumumab: Therapeutic asset, biological trap!, PMID: 29336950
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study, PMID: 30828799
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma, PMID: 26308596
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study, PMID: 32001798
Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma, PMID: 32804408
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX, PMID: 30237262
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies, PMID: 31221782
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment, PMID: 32376855
Daratumumab for the Treatment of Multiple Myeloma, PMID: 29915586
Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma, PMID: 32936436
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial, PMID: 26778538
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR, PMID: 32482541
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens, PMID: 31296574
Amyloidosis: the use of the Daratumumab, PMID: 33331565
CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity, PMID: 32603414
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis, PMID: 32108228
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome, PMID: 31820442
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia, PMID: 29305553
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study, PMID: 33216361
Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma, PMID: 30830601
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab, PMID: 32457357
An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma, PMID: 32659139
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX, PMID: 33149130
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials, PMID: 32470437
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors, PMID: 21187443
Safety of ninety-minute daratumumab infusion, PMID: 32865161
Daratumumab in transplant regimens for myeloma?, PMID: 32818244
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma, PMID: 30136602
Daratumumab: First Global Approval, PMID: 26729183
For research use only. Not for human or drug use.
